This insider selling cluster is immaterial in dollar terms relative to Regeneron's $87.7B market cap. Both sales are small, open-market sales by non-C-suite insiders (EVP Commercial, Director), the academic literature shows cluster sells are weak predictors. Expect no price impact. Monitor for any large C-suite or 10% owner open-market sales exceeding $5M+ to become concerned.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 4 $827.72entry
- T+1 · 2mo ago −2.10%α −1.55% · $810.31
- T+5 · 2mo ago −4.11%α −2.90% · $793.74
- T+20 · 6w ago −12.23%α −12.83% · $726.47
- T+50 · todayOpen
- T+60 · in 14d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Regeneron insiders (EVP Commercial and a director) sold a total of $1.37M in open-market shares over a three-day window, with the EVP selling the bulk ($1.03M). At an $87.7B market cap, the sales represent ~0.0016% of market cap, well below the 0.1% trivial threshold. The exercise of a derivative by the director is non-cash and does not alter the sell-side reading. The trade sizes are modest relative to company size, and the cluster does not exceed any materiality floor.
Key Financial Metrics
Key Facts
- Total open-market insider sales: $1.37M over 3 days (0.0016% of market cap)
- EVP Commercial Marion McCourt sold $1.03M at $857.39 and $850/share, comprising ~75% of the cluster value
- Director Kathryn Guarini sold $340K at $850/share, plus exercised 400 derivative shares at $719.37 (cash portion $287.7K) and 400 shares at $0 (non-cash)
- No insider purchases occurred in this cluster
- Prior 30-day insider activity showed 3 sells totaling $2.3M, consistent pattern of routine sales
Financial Impact
Insider sales of $1.37M represent ~0.0016% of $87.7B market cap, noise level. No material financial impact.
Risk Factors
- Insider selling pattern could intensify if larger trades emerge from CEO/CFO
- No material risk from these small sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REGN-1788507406039 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers